Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Elxleben – page 14

438 clinical trials in Elxleben, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Elxleben at a glance
438
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

438 trials in Elxleben

Open in trial search

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Myelofibrosis+1

Recruiting

Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Study on Stopping Esomeprazole in Patients with Liver Cirrhosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study on Bortezomib for Patients with Severe Autoimmune Encephalitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on the Long-Term Safety of Aficamten (CK-3773274) for Patients with Symptomatic Hypertrophic Cardiomyopathy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Study of TL-895 for Patients with Relapsed or Refractory Myelofibrosis or Indolent Systemic Mastocytosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flixebrutinib
  • Sponsor:Telios Pharma Inc.

Herpes simplex+1

Recruiting

Study on the Effect of Acyclovir in ICU Patients with Pneumonia and Herpes Simplex Virus Type 1 Detected in Lung Fluid

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Study on the Effects of Iptacopan in Patients with Idiopathic Membranoproliferative Glomerulonephritis (IC-MPGN)

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Study on Edoxaban and Drug Combination for Patients with Atrial Fibrillation Needing Anticoagulation After Cardiac Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Hamilton Health Sciences Corporation

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Elxleben

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical research focusing on advanced breast cancer treatment, specifically targeting HER2-negative and hormone receptor-positive cases. This comprehensive study examines treatment efficacy and resistance patterns.

  • Treatment Response Analysis
  • Survival Rate Assessment
  • Progression Monitoring

The research aims to evaluate patient outcomes through detailed analysis of progression-free survival and overall survival rates, providing valuable insights into treatment effectiveness for advanced breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.